Table 2. Outcomes in randomized trials of neuroregenerative and/or cell-transplantation strategies for Parkinson's disease.
Agent | Outcome | Source |
CERE-120 | No significance vs. sham on 1° endpoint | [43] |
GDNF (intraventricular delivery) | No significance vs. sham on 1° outcome; toxicity | [44] |
GDNF (initraputamenal delivery) | No significance vs. sham on 1° endpoint | [45] |
Embryonic mesencephalic tissue | No significance vs. sham on 1° endpoint; toxicity | [46] |
Embryonic mesencephalic tissues | No significance vs. sham on 1° endpoint; toxicity | [47] |
Fetal porcine ventral mesencephalic tissue | No significance vs. sham | [48] |
Retinal epithelial pigmented cells | No significance vs. sham | [49] |